CH273245A - Solution for the radiographic representation of body cavities. - Google Patents
Solution for the radiographic representation of body cavities.Info
- Publication number
- CH273245A CH273245A CH273245DA CH273245A CH 273245 A CH273245 A CH 273245A CH 273245D A CH273245D A CH 273245DA CH 273245 A CH273245 A CH 273245A
- Authority
- CH
- Switzerland
- Prior art keywords
- salt
- solution
- acetic acid
- viscosity
- dissolved
- Prior art date
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive Effects 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 5
- 239000000080 wetting agent Substances 0.000 claims 5
- JYLBTESOPCUQIT-UHFFFAOYSA-N 3,5-diiodo-1H-pyridin-2-one Chemical compound IC1=CNC(=O)C(I)=C1 JYLBTESOPCUQIT-UHFFFAOYSA-N 0.000 claims 3
- PVBALTLWZVEAIO-UHFFFAOYSA-N Diodone Chemical compound OC(=O)CN1C=C(I)C(=O)C(I)=C1 PVBALTLWZVEAIO-UHFFFAOYSA-N 0.000 claims 2
- 230000001419 dependent Effects 0.000 claims 2
- 239000012153 distilled water Substances 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940049964 Oleate Drugs 0.000 claims 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 206010038444 Renal failure chronic Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000000522 chronic kidney disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection
Description
Lösung für die röntgenographische Darstellung von liörperhöhlen.
Zur röntgenographischen Darstellung bestimmter Hohlräume des menschlichen und tierischen Körpers, wie z. B. des Bronchialbaumes, des Uteruscavums, der Tuben usw., wurden bisher ausschliesslich jodierte Öle verwendet. Sie haben den Vorteil der Dickflüssigkeit, dank deren sich gute Schatten erzielen lassen, zugleich aber schwerwiegende Nachteile. Da ihr Jod zuwenig fest gebunden ist, dürfen die jodierten Öle bei Überempfindlichkeit für Jod, bei Hyperthyreoidismus, Kreislaufinsuffizienz, chronischen Nierenleiden und andern Krankheiten, die durch Jod ungünstig beeinflusst werden, nicht verwendet werden.
Ein weiterer Nachteil der jcdierten Öle liegt in ihrer langen Verweilzeit im Organismus. So werden z. B. bei Röntgenaufnahmen der Bronchien durch die langanhaltende Ausschaltung einer grossen Atmungsfläche viele Kranke geschädigt. Zudem verursacht das lange Zeit liegenbleibende Ö1 infolge Abspaltung geringer Jodmengen beträchtliche Gewebeschäden.
Ein weiterer Nachteil der jodierten Öle besteht in ihrer Nichtmischbarkeit mit den serösen Körperflüssigkeiten. Dieser Umstand kann zu : Fehldiagnosen Anlass geben.
Bekanntlich besitzt man in den Derivaten der jodierten Pyridone Kontraststoffe, die sich durch hervorragende Schattengebung, Ungiftigkeit und schnelle Ausscheidung auszeichnen. Wässerige Lösungen jodierter Pyridonderivate sind aber zu dünnflüssig, als dass man sie zur röntgenographischen Darstellung von Körperhöhlen verwenden könnte; ihre Verweilzeit und Haftfestigkeit ist zur Durchführung einer Röntgenaufnahme zu gering.
Bei der röntgenographischen Darstellung von Körperhöhlen bestand schon lange das Bedürfnis nach -einem Kontrastmittel mit folgenden Eigenschaften: völlig inertes- Verhalten im Körper, gute Wasserlöslichkeit, schnelle Ausscheidung aus dem Körper und hohe Viskosität. Von diesen Bedingungen erfüllen die jodierten Öle nur die letzte, während wässerige Lösungen jodierter Pyridonderivate alle ausser der letzten befriedigend erfüllen.
Es wurde nun gefunden, dass bei Lösungen, welche ein unschädliches Salz einer das 1 Carboxymethyl-3, ö-dij odpyridonyl * Radikal enthaltenden Verbindung als Kontraststoff und einen die Viskosität erhöhenden unschädlichen Stoff in Wasser gelöst enthalten, alle oben genannten Erfordernisse vorliegen.
Unter den Viskositätserhöhern hat das Natriumsalz des Celluloseglykolsäureäthers besonders günstige Resultate ergeben; es ist frei von Nebenwirkungen, während bei der Verwendung von Gummi arabicum-Präpa- raten, Polyvinylverbindungen und Cellulosealkyläthern zuweilen Körperschädigungen, wie z. B. Veränderungen des Blutbildes, Allergien, Unterdrückung der Blutgerinnung, Nierenschädigungen usw. beobachtet werden.
Gegenstand der Erfindung ist eine für die röntgenographische Darstellung von Körper
An Stelle des Diäthanolaminsalzes können die Salze anderer organische, r Basen, z. B. des Äthanolamins, Triäthanolamins, Morpholins, verwendet werden.
Solution for the radiographic representation of body cavities.
For the radiographic representation of certain cavities in the human and animal body, such as. B. the bronchial tree, the uterine cavity, the tubes, etc., so far only iodized oils have been used. They have the advantage of being thick, thanks to which good shadows can be achieved, but at the same time have serious disadvantages. Since their iodine is not firmly bound, the iodized oils must not be used in the event of hypersensitivity to iodine, hyperthyroidism, circulatory insufficiency, chronic kidney disease and other diseases that are unfavorably influenced by iodine.
Another disadvantage of the jcdised oils is their long retention time in the organism. So z. B. in x-rays of the bronchial tubes many sick people are injured due to the long-lasting elimination of a large respiratory area. In addition, the oil that remains for a long time causes considerable tissue damage due to the elimination of small amounts of iodine.
Another disadvantage of iodized oils is that they cannot be mixed with serous body fluids. This fact can lead to: Misdiagnosis.
It is known that the derivatives of the iodinated pyridones contain contrast substances which are distinguished by excellent shading, non-toxicity and rapid excretion. Aqueous solutions of iodized pyridone derivatives are too thin to be used for the radiographic representation of body cavities; their dwell time and adhesive strength are too short to carry out an X-ray exposure.
In the radiographic representation of body cavities, there has long been a need for a contrast medium with the following properties: completely inert behavior in the body, good solubility in water, rapid elimination from the body and high viscosity. Of these conditions, the iodized oils only meet the last, while aqueous solutions of iodized pyridone derivatives satisfy all but the last.
It has now been found that solutions which contain a harmless salt of a compound containing the 1-carboxymethyl-3, δ-diiodopyridonyl * radical as a contrast substance and a harmless substance which increases the viscosity, dissolved in water, meet all of the above requirements.
Among the viscosity-increasing agents, the sodium salt of cellulose glycolic acid ether has given particularly favorable results; it is free of side effects, while the use of gum arabic preparations, polyvinyl compounds and cellulose alkyl ethers sometimes causes physical damage, such as e.g. B. Changes in the blood count, allergies, suppression of blood clotting, kidney damage, etc. can be observed.
The invention relates to a radiographic representation of the body
Instead of the diethanolamine salt, the salts of other organic bases, e.g. B. of ethanolamine, triethanolamine, morpholine, can be used.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH273245T | 1948-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH273245A true CH273245A (en) | 1951-01-31 |
Family
ID=4479164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH273245D CH273245A (en) | 1948-10-14 | 1948-10-14 | Solution for the radiographic representation of body cavities. |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH273245A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2870063A (en) * | 1955-07-05 | 1959-01-20 | Mallinckrodt Chemical Works | X-ray contrast composition comprising substantially amylose-free amylopectin in aqueous solution of contrast agent |
WO1980001244A1 (en) * | 1978-12-19 | 1980-06-26 | Bykgulden Lomberg Chem Fab | X-ray contrast media solutions |
EP0012926A1 (en) * | 1978-12-19 | 1980-07-09 | Byk Gulden Lomberg Chemische Fabrik GmbH | Solutions of X-ray contrast agents |
-
1948
- 1948-10-14 CH CH273245D patent/CH273245A/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2870063A (en) * | 1955-07-05 | 1959-01-20 | Mallinckrodt Chemical Works | X-ray contrast composition comprising substantially amylose-free amylopectin in aqueous solution of contrast agent |
WO1980001244A1 (en) * | 1978-12-19 | 1980-06-26 | Bykgulden Lomberg Chem Fab | X-ray contrast media solutions |
EP0012926A1 (en) * | 1978-12-19 | 1980-07-09 | Byk Gulden Lomberg Chemische Fabrik GmbH | Solutions of X-ray contrast agents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4242926C2 (en) | Dialysis solution for peritoneal dialysis | |
CH414063A (en) | X-ray contrast media | |
EP0287805A1 (en) | Preserved hair and skin cleaning compositions, and use of a combination of preservatives | |
DE112019006000T5 (en) | A tooth desensitizer for the deep sealing of dentinal tubules and the prevention of biofilm formation | |
CH273245A (en) | Solution for the radiographic representation of body cavities. | |
DE806701C (en) | Contrast media for the roentgenographic representation of body cavities and processes for their production | |
EP0494910B1 (en) | Eye-drops | |
DE858457C (en) | Process for the production of contrast media for diagnostic radiology | |
DE711488C (en) | Process for the production of a disinfectant | |
DE237408C (en) | ||
DE650751C (en) | Process for the production of long-lasting, glycol-containing solutions of alkali salts from barbituric acid decoctions | |
DE629841C (en) | Process for the preparation of an aqueous quinine solution for injection purposes | |
DE657129C (en) | Process for the production of solutions or extracts from bacteria, pollen or other plant cells | |
AT114598B (en) | Process for the production of antiseptic agents. | |
DE1234931B (en) | X-ray contrast media | |
DE1593155C (en) | Process for the production of complex chlorhexidine / iodine compounds and their use as disinfectants | |
DE526738C (en) | Disinfection method | |
DE476992C (en) | Process for the production of disinfectants | |
DE955060C (en) | Process for the preparation of penicillin salts | |
DE718003C (en) | Disinfectants | |
AT200257B (en) | ||
DE915851C (en) | Process for the preparation of solutions containing tyrothricin and streptomycin or dihydrostreptomycin | |
DE704549C (en) | Process for the production of polyjodoxyphenylphenyl acetic acids | |
AT218175B (en) | X-ray contrast medium to visualize the biliary tract | |
AT100211B (en) | Process for the preparation of new organic arsenic compounds. |